CoChat

Future of ToxicologyIron Chelators and Differing Modes of Action and Toxicity: The Changing Face of Iron Chelation Therapy

Kalinowski, Danuta S., Richardson, Des R. · 2007 · Chemical Research in Toxicology

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Iron (Fe) chelation therapy was initially designed to alleviate the toxic effects of excess Fe evident in Fe-overload diseases. However, the novel toxicological properties of some Fe chelator-metal complexes have shifted appreciable focus to their application in cancer chemotherapy. Redox-inactive Fe chelator complexes are well suited for the treatment of Fe-overload diseases, whereas Fe chelator complexes with high redox activity have shown promising results as chemotherapeutics against cancer. Within this perspective, we discuss the different modes of action and toxicological profiles of Fe chelators, including analogues of 2-pyridylcarboxaldehyde isonicotinoyl hydrazone, di-2-pyridylketone isonicotinoyl hydrazone, di-2-pyridylketone thiosemicarbazone, and the clinically trialed chelator 3-aminopyridine-2-carboxaldehyde thiosemicarbazone. The potential application of these agents in the changing face of Fe chelation therapy is discussed.

Overview

Integrity signals

Registry

Crossref · 10.1021/tx700039c

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 16 references

Research works printed but not linked: 28

  1. Liu Z. D., 2002, Med. Res. Rev., 22, 64
  2. Lovejoy D. B., 2000, Complexes of gallium(III) and other metal ions and their potential in the treatment of neoplasia. Expert Opin. Invest. Drugs 9, 1257−1270
  3. Olivieri N. F., 1997, Iron-chelating therapy and the treatment of thalassemia. Blood 89, 739−761
  4. Wong A., 1999, The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum. Mol. Genet. 8, 425−430
  5. Shinar E., 1990, Semin. Hematol., 27, 82
  6. Kolberg M., 2004, Biochim. Biophys. Acta, 1699, 34
  7. Thelander L., 1983, Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: possible regulation mechanism. Biochem. Biophys. Res. Commun. 110, 859−865
  8. Gao J., 2001, IV: The mechanisms involved in inhibiting cell-cycle progression. Blood 98, 842−850.
  9. Nurtjahja-Tjendraputra E., 2006, Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood, in press
  10. Armstrong C. M., 2003, Eur. J. Inorg. Chem., 2003
  11. Wong C. S., 2004, Biochim. Biophys. Acta, 1739, 80
  12. Richardson D. R., 2001, Biochim. Biophys. Acta, 1536
  13. Chaston T. B., 2004, Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves fenton-derived free radical generation. Clin. Cancer Res. 10, 7365−7374
  14. Sartorelli A. C., 1971, Mechanism of inhibition of ribonucleoside diphosphate reductase by α-(N)-heterocyclic aldehyde thiosemicarbazones. Biochem. Pharmacol. 20, 3119−3123
  15. Sartorelli A. C., 1967, Inhibition of the growth of sarcoma 180 ascites cells by combinations of inhibitors of nucleic acid biosynthesis and the cupric chelate of kethoxal bis-(thiosemicarbazone). Cancer Res. 27, 1614−1619
  16. Agrawal K. C., 1978, The chemistry and biological activity of α-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Prog. Med. Chem. 15, 321−356
  17. Yuan J., 2004, Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 104, 1450−1458
  18. Whitnall M., 2006, Proc. Natl. Acad. Sci. U.S.A. 103
  19. Shao J., 2006, A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Mol. Cancer. Ther. 5, 586−592
  20. Cory J. G., 1994, Inhibitors of ribonucleotide reductase: Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones. Biochem. Pharmacol. 48, 335−344
  21. Finch R. A., 2000, Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem. Pharmacol. 59, 983−991
  22. Shao J., 2004, Cancer Res., 64, 6
  23. Cooper C. E., 1996, J. Biol. Chem., 271
  24. Chen C. H., 2002, Eur. J. Cancer, 38, S26
  25. Yen Y., 2004, A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother. Pharmacol. 54, 331−342
  26. Liu Z. D., 2002, Coord. Chem. Rev., 232
  27. Richardson D. R., 1995, The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86, 4295−4306
  28. Abbreviations AP, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone

Cited by

Metadata

Authors
Kalinowski, D. S., & Richardson, D. R.
Affiliations
The University of Sydney (AU)
Corresponding author
Richardson, Des R.
Venue
Chemical Research in Toxicology
Published
2007-04-03
Volume
20
Issue
5
Pages
715-720
ISSN
  • 0893-228X (ISSN-L)
  • 1520-5010
OpenAlex
W2071434358
Cited by
145
References
15
Citations by year
2026: 2 · 2025: 6 · 2024: 9 · 2023: 6 · 2022: 6 · 2021: 7 · 2020: 9 · 2019: 9 · 2018: 10 · 2017: 6 · 2016: 11 · 2015: 9 · 2014: 4 · 2013: 3 · 2012: 7
FWCI
6.35
Type
journal article
Language
en
Open access
closed
Locations
  • Chemical Research in Toxicology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
  • Physical Sciences › Environmental Science › Health, Toxicology and Mutagenesis › Heavy Metal Exposure and Toxicity
Keywords
iron chelators, cancer chemotherapy, redox activity, hydrazone complexes, thiosemicarbazone complexes, iron chelation therapy
MeSH terms
Humans, Hydrazones, Iron Chelating Agents, Isoniazid, Pyridines, Pyridoxal, Structure-Activity Relationship, Thiosemicarbazones, Toxicology, Chelation Therapy, Iron Overload

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.